(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 4.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 283.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Mimedx Group's revenue in 2025 is $393,442,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2025 to be $58,221,920,746, with the lowest MDXG revenue forecast at $55,782,678,187, and the highest MDXG revenue forecast at $60,228,705,001. On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $62,986,367,201, with the lowest MDXG revenue forecast at $59,086,837,355, and the highest MDXG revenue forecast at $67,179,139,322.
In 2027, MDXG is forecast to generate $70,350,006,547 in revenue, with the lowest revenue forecast at $64,993,151,456 and the highest revenue forecast at $75,203,314,297.